Severe Asthma Market Forecast 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies, and Companies by DelveInsight

DelveInsight's report titled "Severe Asthma Market Insights, Epidemiology, and Market Forecast - 2034" comprehensively analyzes Severe Asthma. The report provides a comprehensive analysis of historical and projected epidemiological data, covering Total Diagnosed Prevalent cases of Asthma, Severity-specific Diagnosed Prevalent cases of Asthma, and Type-specific Diagnosed Prevalent cases of Severe Asthma.

Key Takeaways from the Severe Asthma Market Forecast Report
• The increase in Severe Asthma Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight's analysis, the Severe Asthma Market is anticipated to witness growth at a considerable CAGR.
• Total diagnosed prevalent cases of asthma in the 7MM were found to be around 43 million cases in adults and about 11 million cases in the pediatric population in the year 2023. These cases are expected to rise significantly by 2034.
• The United States accounted for around 26 million diagnosed prevalent cases of asthma (including both pediatric and adult population), in 2023.
• The leading Severe Asthma Companies working in the market include AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, and others.
• Promising Severe Asthma Therapies in the various stages of development include Mepolizumab 100 MG, Verekitug (UPB-101), FB704A, Reslizumab, and others,
• May 2024:- Incyte Corporation- A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma. The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function.
• May 2024:- AstraZeneca- Asthma Control in Severe Asthma Patients Treated With Tezepelumab: A Prospective, Observational, Real-World Evidence Study (ASCENT). This study will complement evidence obtained from randomized controlled trials and provide new data focusing on the holistic and patient reported outcome (PRO).

Discover which therapies are expected to grab the Severe Asthma Market Share @ Severe Asthma Market Outlook- https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Asthma Overview
Severe asthma is a type of asthma that is difficult to control despite treatment with high doses of medications. It is characterized by frequent and severe asthma attacks, which can significantly impair daily activities and quality of life. People with severe asthma often experience symptoms such as wheezing, shortness of breath, chest tightness, and coughing, which can be triggered by various factors including allergens, air pollution, exercise, and respiratory infections.

Severe Asthma Epidemiology Segmentation in the 7MM
The epidemiology section on Severe Asthma offers an analysis of past and present patient populations, along with projected trends across seven major countries (7MM). Drawing from multiple studies and expert opinions, it aims to elucidate the underlying factors driving current and anticipated trends. Additionally, this segment of the report presents data on the diagnosed patient population, highlighting trends and underlying assumptions.

Learn more about Severe Asthma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Asthma Marketed Therapies

• Cinqair (reslizumab): Teva Pharmaceutical
Cinqair injection is a humanized interleukin-5 antagonist monoclonal antibody for add-on maintenance treatment of adult patients with severe asthma and with an eosinophilic phenotype, developed by Teva Pharmaceuticals. Cinqair is for intravenous infusion only. It is not to be administered as an intravenous push or bolus. The recommended dosage regimen is 3 mg/kg once every 4 weeks administered by intravenous infusion over 20-50 min.

• Fasenra (benralizumab): AstraZeneca
Fasenra (benralizumab) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution for subcutaneous injection. Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with a dissociation constant of 11 pM, developed by AstraZeneca. The IL-5 receptor is expressed on the surface of eosinophils and basophils. Benralizumab is produced in Chinese hamster cells by recombinant DNA technology.

Severe Asthma Emerging Drugs Profile

• GSK3511294 (Depemokimab): GlaxoSmithKline
GSK3511294 (depemokimab), which GlaxoSmithKline is developing to treat severe eosinophilic asthma, is a humanized anti-interleukin (IL)-5 monoclonal antibody. As a new biological entity, it is engineered to ensure high affinity and long-acting suppression of IL-5 functions. IL-5 are cytokines responsible for the proliferation, activation, and survival of eosinophils, thus making them a proven treatment target for severe asthma patients with higher levels of eosinophils.

• PT010: AstraZeneca
PT010 (Breztri/Trixeo/ BGF MDI (budesonide-glycopyrrolate-formoterol inhalation)) being developed by AstraZeneca, is a fixed-dose combination of micronized budesonide, an inhaled corticosteroid (ICS), micronized glycopyrrolate (an anticholinergic), and micronized formoterol fumarate, an inhaled long-acting beta2-adrenergic agonist (a LABA), for oral inhalation administered via a pressurized metered-dose inhaler (pMDI) using Aerosphere delivery technology.

To learn more about Severe Asthma treatment guidelines, visit @ Severe Asthma Treatment Market Landscape- https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Severe Asthma Market Outlook
The Severe Asthma market outlook is driven by a multifaceted approach aiming to alleviate symptom burden while minimizing adverse events and maintaining normal activity levels. Guideline-based management emphasizes disease severity and the selection of appropriate medical therapies to control symptoms and mitigate exacerbation risks.

Severe Asthma Drugs Uptake
The drug chapter of the Severe Asthma report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of Severe Asthma clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Severe Asthmas.

Severe Asthma Companies
AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, and others.

Learn more about the FDA-approved drugs for Severe Asthma @ Drugs for Severe Asthma Treatment- https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Severe Asthma Market Report
• Coverage- 7MM
• Severe Asthma Companies- AstraZeneca plc, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb, Eli Lilly and Company, Vertex Pharmaceuticals Incorporated, Amgen Inc., AbbVie Inc., Genentech, Inc., Gilead Sciences, Inc., Biogen Inc., CSL Limited, and others.
• Severe Asthma Therapies- Mepolizumab 100 MG, Verekitug (UPB-101), FB704A, Reslizumab, and others,
• Severe Asthma Market Dynamics: Chronic Kidney Disease Market Drivers and Barriers
• Severe Asthma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Severe Asthma Drugs in development @ Severe Asthma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/severe-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1 Key Insights
2 Report Introduction
3 Severe Asthma Market Overview at a Glance
4 Severe Asthma Epidemiology and Market Methodology
5 Executive Summary of Severe Asthma
6 Key Events
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 Severe Asthma: Seven Major Market Analysis
13 Key Opinion Leaders' Views
14 SWOT Analysis
15 Unmet Needs
16 Reimbursement and Market Access
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

List of Important Links-

https://chutpatti.com/read-blog/18705
https://www.djjmeets.com/germandennydones
https://demo.sngine.com/germandennydones
https://webyourself.eu/dennydones99
https://www.dr-ay.com/blogs/176973/Healthcare-Consulting-Services-Solutions-DelveInsight
https://flokii.com/users/view/40325/activity_id:257060
https://jobhop.co.uk/profile/287120
https://www.vevioz.com/read-blog/132195
https://www.wikipostings.com/author/germandennydones/
https://soundcloud.com/dennydones
https://developer.cisco.com/user/profile
https://www.rafabasa.com/author/germanydennydones/
https://tinhte.vn/members/denny-dones.3019555/
https://blog.seedly.sg/profile/denny-dones/
https://www.indiadivine.org/content/profile/104123-germandennydones/?tab=field_core_pfield_15
https://wellfound.com/u/dennydones9
https://www.digitaldoughnut.com/contributors/germandennydones
https://joyrulez.com/dennydones9193

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.